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Summary Infection from Mycobacterium tuberculosis results in the death of three
million people worldwide per annum of which an estimated one thousand are in Saudi
Arabia. The WHO has set a target for successful treatment of 85% but Saudi Arabia
is currently not meeting that target. We believe that the ﬁrst step in improving
the control of tuberculosis in Saudi Arabia is to improve and unify the standards of
diagnostic services and laboratories responsible for tuberculosis. This paper reviews
the current status and suggests possible improvements.
© 2009 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier
Ltd. All rights reserved.
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Introduction
Worldwide situation
The WHO estimated that worldwide there were an
estimated 8.9 million new cases of TB in 2004,
with 3.9 million new smear positive, with Africa
(24%), South East Asia (35%) and the Western Paciﬁc
region (24%) together accounted for 83% of the
global burden. Human immunodeﬁciency virus (HIV)
is a signiﬁcant contributor in some areas, notably
sub-Saharan Africa and the United States where
31 and 26%, respectively, of new cases in adults
were attributable to HIV and worldwide tubercu-
losis accounted for 11% of AIDS deaths worldwide
[19,23].
This static global ﬁgure does not reﬂect greater
variations and dynamics within certain regions.
The increases in sub-Saharan Africa and the for-
mer Soviet Union are the steepest. Industrialized
countries have had steady or declining incidences,
but increasing rates among foreign-born nationals
or foreign citizen [21,31]. In London boroughs, TB
notiﬁcation rates have been shown to vary by a
factor of 10 [21]. IS6110 typing was used to study
strains of Mycobacterium tuberculosis collected in
London between 1995 and 1997, and revealed that
most tuberculosis in London is due to reactivation
of previous infection or importation of infection by
recent immigrants [20].
Better surveys are needed in high burden coun-
tries requiring high quality routine surveillance.
Ultimately effective control of the disease requires
an understanding of the dynamics of disease trans-
mission, implementation of accurate and rapid
diagnostics and typing methodologies, and efﬁca-
cious treatment. The logistics of implementation
of these among poor, migrating and rural people
further the challenge [33].
Epidemiology of TB in Saudi ArabiaThe WHO estimates of the disease burden in Saudi
Arabia are found in Table 1. According to the WHO
the incidence of TB all forms, smear positive TB and
deaths from TB each rose by 6.2% between 1990 and
2004, but the prevalence declined. These ﬁgures
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uggest that the notiﬁcation rates of TB in Saudi
rabia increased during this period, as did the suc-
essful treatment rate, such that a decrease in the
otal number of cases was seen at the same time
s the incidence and death rates increased [34,40].
espite the noticeable improvements on notiﬁca-
ion and successful treatment rates yet Saudi Arabia
as a moderate infection rate in comparison with
he other countries-Table 2.
Saudi Arabia has interesting and special pop-
lation dynamics. There are up to six million
xpatriates mainly from endemic regions, in South
nd South East Asia and over two million pilgrims
isiting the holy cities located in the western region
f the Kingdom each year, with the majority of
ilgrims coming from endemic areas. There are
ifferences in the rate of TB infection in differ-
nt regions of the country. For instance in Jeddah
Sea and Air ports for pilgrims arriving into Mecca)
he infection rate can reach up to 64 cases per
00,000 compared with 32 per 100,000 in Riyadh
Central). The higher rate in Jeddah may have
een caused by inﬂux of pilgrims [1,9,10,25,32].
study of 64 patients admitted to two hospitals
ith pneumonia during the 1994 Hajj pilgrimage
ited M. tuberculosis as being the most com-
on cause, infecting 20% of patients [17]. Nearly
ll of the patients were from developing coun-
ries and the authors suggested that older age,
xhaustion, malnutrition and prior use of amox-
cillin were contributing factors. A retrospective
tudy of medical records of 157 patients with a
nal diagnosis of tuberculosis was performed at
he King Abdul Aziz Hospital, Jeddah, between
uly 1999 and July 2001. Fifty-seven patients (36%)
ere Saudis and 100 patients (64%) were non-
audis with a mean age of 33 years (±15.33). A
rospective study of health care workers at the
ing Abdulaziz Hospital, Jeddah, found the rate
f positive tuberculin skin testing was signiﬁcantly
igher among non-nationals; 78.9% overall, 60.0%
or Saudis compared with 81.8% for non-Saudis
p < 0.01) [30]. The mean response size for non-
audis (13.9 +/7mm) was signiﬁcantly larger than
or Saudis (8.9 +/7mm, p < 0.001). These data sug-
est that visitors and immigrants to Saudi Arabia are
ssociated with a higher rate of tuberculosis dis-
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Table 1 Figures from WHO report showing the estimation incidence, prevalence and mortality rate caused by
tuberculosis in Saudi Arabia.
1990 2004 Percent increase References
Incidence, all forms 8,919 (50/100,000) 9,471 (40/100,000) 6.2 [19,35]
HIV positive — 4 (<1/100,000) — [19,35]
Incidence, smear
positive
4,013 (25/100,000) 4,262 (18/100,000) 6.2 [19,35]
HIV positive
Incidence, smear
positive
— 1 (<1/100,000) — [19,35]
Prevalence 14,069 (86/100,000) 13,267
Mortality 1,035 (6/100,000) 1,099
Table 2 Infection rate in Saudi Arabia compared with
other countries.
Country Infection rates Reference
USA 5.2 per 100,000 [22]
UK 35 per 100,000 [22]
Saudi Arabia 32—64 per 100,000 [33]
India 180 per 100,000 [35]
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[20,22,36], and introduction of a central referralSub-Saharan Africa 290 per 100,000 [23]
South Africa 509 per 100,000 [23]
ase, which is in agreement with data from Europe
37].
Recent report by Ministry of Health showed
hat TB infection rate has risen again. The report
howed that the total cases of TB in the country
ave reached 3878 cases in 2007 with incre-
ent rate of 0.6 per 100 thousand compared
o 2006 (3854 cases). Also the report showed
hat the percentages of Saudi among the total
ases were 52.7 compared to 47.4 of non-Saudis
ttp://www.moh.gov.sa/statistics/stats2007/Book
20Seha02.pdf.
ecent ﬁndings
total of 1505 clinical isolates of M. tuberculo-
is, isolated between 2002 and 2005 from seven
egions of Saudi Arabia were studied. The sample
tudied showed a male to female sex-ratio of 1.27
ith half of the cases among foreign-born and 47%
ithin the age-group of 21—40 years, a total resis-
ance rate of 19.7% and multiple drug resistance of
.5%. Upon spoligotyping, a total of 387 individual
atterns were obtained (clustering rate of 86.4%,
82 clusters containing between 2 and 130 isolates
er cluster). A total of 94% of the strains matched
o the spoligotype patterns in an international
atabase SpolDB4 database (http://www.pasteur-
uadeloupe.fr:8081/SITVITDemo). Nearly 81% of
he isolates in this study belonged to the estab-
l
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l(55/100,000) 5.7 [19,35]
(5/100,000) 6.2 [19,35]
ished phylogeographic clades; Central Asian-CAS
2.5%, ill-deﬁned T clade 19.5%, East African
ndian-EAI 13.5%, Haarlem 7.5%, Latin American
editerranean-LAM 7.2%, Beijing 4.4%, Manu 2.7%,
0.9%, and Bovis 0.9%. Two clonal complexes
ith unique spoligotyping signatures (octal codes
03777707770371, and 467777377413771) speciﬁc
o Saudi Arabia were identiﬁed. These belonged to
AS and EAI clades, respectively, as conﬁrmed upon
econdary typing using mycobacterial interspersed
epetitive units (MIRUs). The results obtained
nderline the predominance of historic clones of
he principal genetic group 1 (PGG1), which are
esponsible for roughly 45% of all tuberculosis cases
n Saudi Arabia. The high rate of clustering observed
ight be an indication of rapid ongoing transmission
ithin certain communities and/or subpopulations
n Saudi Arabia [8].
iagnosis and treatment of tuberculosis
icroscopy and culture
n Saudi Arabia detection of M. tuberculosis is by
iehl-Neelson staining, conﬁrmation is by culture
nd isolation and speciation is by niacin and nitrate
eactions. Drug susceptibility testing employs the
ycobacterial Growth Indicator Tube (MGIT) system
Becton Dickenson, Germany) in some laboratories,
olid media (Lowenstein Jensen) in others, or is
ot performed at all. Recent visits to several lab-
ratories in Saudi Arabia have shown a number of
aboratories to require improvement in standards
f equipment, training and record keeping [7] and
ersonnel observation. Implementation of a qual-
ty assurance examination system, such as NEQUASaboratory where speciation and drug susceptibil-
ty testing can be performed may help to level
tandards and comparability between diagnostic
aboratories. Importantly, it would also provide
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access to testing for institutions that lack their own
facilities and help to meet and raise standards set
by the National Tuberculosis program (NTP).
National Tuberculosis program (NTP) and
Directly Observed Therapy (DOTS)
In 1992, the Ministry of Health established a
National Tuberculosis Control Committee to imple-
ment a control program throughout Saudi Arabia
and in 1999 the committee decided to imple-
ment DOTS. The NTP in Saudi Arabia constitutes a
manual, recording and reporting system, training,
laboratory and X-ray services. Treatment services
and drug and equipment supply is funded by the
Ministry of Health. In Saudi Arabia there are several
institutions providing healthcare for patients with
tuberculosis; National Guard health affairs, Mili-
tary Hospitals, Security forces Hospitals, university
hospitals, private hospitals and Ministry of Health
Hospitals. Patients attending private hospitals sus-
pected of having TB are referred to government
hospitals. There is no central system of record
keeping, such that a patient currently receiving
treatment at one institution may present to another
with tuberculosis and be recorded as a new case
[7]. All institutions should report to the Ministry of
Health, the body responsible for collecting data on
tuberculosis, but we believe that this is not being
adhered to [7]. Saudi Arabia’s DOTS success rate
is comparatively well below international ﬁgures
(Table 3). As successful treatment is dependent on
quality assured bacteriology, Saudi Arabia needs
improvements to a number of laboratories across
the country.
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Table 3 Shows the success rates in treating drug resistant
in different countries. Once again the data showed that Sau
Country DOTS success rate drug susceptible
Saudi Arabia 65.0
China 85
Europe 83.0
Sub-Saharan Africa 81.0
Thailand 85.0
Table 4 Shows the mono and multi-drug resistance rates i
City RIF Percent of drug resistance
INH PZA ETB
Jeddah/Taif (West) 20.0 28.7
Riyadh (Central) 2.8 9.1
Jazan (South) 43.0 80.0
Dammam (East) 0.2 6.0
RIF = rifampicin, INH = isoniazid, PZA = pyrazinamide, ETB = ethambuS.A. Al-Hajoj
Empirical anti-tuberculosis therapy used in Saudi
rabia usually includes three to four ﬁrst line
rugs including isoniazid, rifampicin, ethambutol,
yrazinamide and streptomycin. Despite the imple-
entation of the NTP and DOTS, the number of
atients effectively treated in Saudi Arabia has
allen below the WHO target of 85% with drug
esistance, noncompliance and over the counter
ccess to anti-tuberculosis treatment being con-
ributing factors [5,15,37]. A retrospective study
as conducted, which included 147 patients with
ulture proven diagnosis of tuberculosis seen at
he King Khalid National Guard Hospital, Jeddah,
etween June 1993 and June 1999. One hun-
red and twenty-six patients completed treatment
nd, with patients lost to follow up considered as
reatment failures, treatment success was 102/147
69.4%) and failure 45/147 (30.6%). Noncompliance
nd drug resistance were cited as being signiﬁcantly
ssociated with treatment failures [37].
iscrepancies in drug-resistance proﬁle
here are several studies that have shown differ-
nt rates of tuberculosis drug resistance across
he country over the last 20 years (Table 4). How-
ver, these studies should be treated with caution
or the following reasons: for some studies the
ethodologies were not clearly described, some
re now out of date, the studies were retro-
pective, none followed the WHO guidelines for
rug-resistance surveys and some studies are con-
radictory [3—6,11—14,16,18,26,27,29,38,39,41].
tuberculosis using directly observed therapy [D.O.T.S]
di Arabia fall behind the set target 85% by WHO.
TB % DOTS success rate MDR—TB % Reference
NA [19]
57.0 [19]
57.0 [22]
72.7 [23]
57.0 [19]
n different cities in Saudi Arabia.
STR % MDR—TB Reference
7.9 6.9 22.8 25.0 [3,28]
5.0 2.8 1.6 11.8 [3,13,16,18,30]
Se N/A 53.0 44.0 [3,27]
S S 0.7 7.0 [3,11,14]
tol STR = streptomycin, S = sensitive, N/A = not available.
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cuberculosis in Saudi Arabia
oving forward
xisting committees should update the NTP guide-
ines for Saudi Arabia in accordance with World
ealth Organization (WHO) established guidelines.
he NTP guidelines should aim to address any
ack of human resources and expertise. Lack of
uman resources development is an obstacle in
audi Arabia and this lack of attention results in
bsence/deﬁciency of training and continuing edu-
ation [7]. Furthermore, diagnosis protocols should
e updated in line with international standards and
hould be adopted unanimously across all institu-
ions providing tuberculosis facilities, in order that
tandards can be uniﬁed and results compared.
hese should be implemented to improve the speed
nd accuracy of diagnosis. Communication between
aboratories should be strengthened and ongoing
ducation for laboratory and clinical staff may also
e of value. The different frequencies of resis-
ance across the country (Table 4) probably reﬂect
egional differences in both epidemiology and labo-
atory standards. Signiﬁcantly, there is no adopted
tandard methodology applied across the country
7]. We suggest that, at least as a short-term mea-
ure, laboratories with inadequate infrastructure
r lack of trained personnel to perform the sus-
eptibility testing should send their isolates to the
earest center, provisions and/or funding for which
eed to be provided by the Ministry of Health.
egistry
o improve epidemiological surveys a central
atabase in which all cases should be registered and
pdated at each consultation would enable clini-
ians to monitor patients that move from one region
o another and allow continual access to treatment
ecords. This would prevent patients registering
s new patients at more than one center, without
estricting their movement, and would facilitate
OTS programs across the country. Such a database
ould enable accurate determination of notiﬁca-
ion rates, treatment success and failures and drug
esistance.
ocial health workers involvement and
creening
ocial health workers may help to improve compli-
nce by actively following patients to ensure that
edications are taken according to the physician’s
rescription. This may compliment the DOTS pro-
ram by actively seeking out patients who do not
ttend appointments. Screening of patients enter-
i
i
r
d21
ng the country may also help to reduce the number
f infections brought into the country by immigra-
ion and visitors, as is done elsewhere, but the cost
fﬁcacy beneﬁt is not clear [24,31,35].
olecular techniques
olecular techniques for typing strains of M.
uberculosis are essential to identify cross con-
amination, outbreaks and transmission to be
nvestigated [28]. In Saudi Arabia Restriction
ragment Length Polymorphisms (RFLPIS6110) and
poligotyping have already shown that inter-
ationally recognized multi-drug-resistant strains
Beijing) to be present [8]. In addition many
mported families also were identiﬁed using, molec-
lar tools. In another studies we identiﬁed cross
ontamination event and cross infection within a
amily. The wider implementation of molecular
esting would enhance the understanding of the
ynamics of M. tuberculosis and its dissemination
ithin the country. Therefore, we propose that
ll isolates after initial diagnosis and identiﬁca-
ion should be transferred to a specialized center
or genotyping and that genotypic results be linked
ith the patient’s ﬁle for follow up and future use.
atabase
e think it is the time to create a database in
hich we should have all the patients registered.
he registry of the patients should be based on
he national identiﬁcation card and for the resi-
ents the Iqamma number should be used. Also the
atabase should contain the pattern of susceptibil-
ty tests. Moreover we proposed that all isolates
hould be genotyped and all strains identiﬁcation
hould be linked to the patient. This is extremely
mportant so we can differentiate on the second
pisode either the patients came back with new
nfection, treatment failure, or with reactivation
f an old infection. Also it is possible to know
rom genotype either the strain is virulent such
s Beijing genotype or not. Genotyping also can
ecognize the outbreaks and the ongoing transmis-
ion. We at Tuberculosis Research Unit were able
o create such database. What is missing in such
atabase is the information from the rest of the
ountry. Also we would like to see such database
s accessible by all concerned chest physicians and
nfectious diseases and public health physicians
unning the National Tuberculosis program. The
atabase should be updated on a continuous bases.
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Ongoing transmission
Recent data showed that the country, despite the
efforts by the health care takers, has ongoing
transmission among citizens and residents equally.
Also the data showed that the ongoing transmis-
sion is caused by both imported and endogenous
strains (clades/families). These evidences raised
the question about what can be done to break
the cycle of transmission. It does not matter how
much we treat and it does not matter which strat-
egy we used, either Direct Observed Therapy, or
any other strategy, we believe unless we break
the cycle of ongoing transmission, TB infection
will remain as ever uncontrollable disease. We
believe there are reasons behind such active on
going ongoing transmission including the fact that
some patients (especially illegal residents) escape
follow up after 2—3 weeks of starting the treat-
ment from hospitals fearing the deportation after
the completion of treatment. Unfortunately those
individuals seek refuge within local nationals house-
hold or among farmers in large farms. They are
involved in creation of drug-resistance strains as a
result of their failure to complete the treatment
and disease transmission. Other reasons including
the lack of case ﬁnding strategies, many expa-
triates with TB hide a way after Hajj and Umra
seasons.
Strategies of case ﬁnding should be activated and
large screening studies should take place across the
country. For expatriates we believe the deportation
policy should be reversed so no one feels the fear
of the deportation and then they run a way from
hospital after the slight improvement they noticed.
Screening program
Latent TB is the main source for active TB dis-
ease. According to the World Health Organization
one third of the mankind is infected with latent TB.
In Saudi Arabia the information about how much
people are infected with latent TB is scarce. We
do not know for instance what are the percent-
ages of latent infection among Health care workers,
prisoners, and contact groups. It is essential to
screen at least those at high risk for latent TB
using most reliable tools. Recently FDA approved
two new interferon- gama release assays (IGRAs)
which are are now available for the diagnosis of
LTBI: the QuantiFERON-TB Gold (Cellestis, Victoria,
Australia) and the T-SPOT.TB (Oxford Immunotec,
Oxford, UK). Both tests are better than skin test
in the speciﬁcity and sensitivity to diagnose latent
TB. Also they have advantages over the skin test;
including ease in performance, no need for sec-
FS.A. Al-Hajoj
nd visit and the test reading is not subjective like
kin test. One of these two tests should be imple-
ented to screen most vulnerable groups within
he communities to detect latent TB or even catch
hose whom recently converted to sero-positive [2].
he advantages of these new tests in addition to
hat was mentioned that they, unlike skin test, do
ot cross react with other mycobacteria such envi-
onmental mycobacteria or do not react with BCG
accine it self.
ummary
t is clear that tuberculosis in Saudi Arabia is in need
or attention. This is supported by the increase in
he infection rate 0.6% during 2007 compared to
006 infection rate. This may be an indication of
he improvements of the case detection but also
ould means that the rate is on increase. Several
actors may inﬂuence the rate of infection in Saudi
rabia. Theses factors include the huge number of
xpatriate worker force who are residents of this
ountry. Also religious visitors whom target Mecca
nd Madina for Hajj and Umra. This is because
oth laborers and visitors mainly come form TB
ndemic countries. Recent data that showed that
/3 of genotyped isolates are indeed imported
trains [8]. The National TB program and status of
aboratories are another two factors that play a
ajor role in controlling the disease. A number of
mprovements to tuberculosis disease control and
nderstanding of epidemiology have been outlined
n this review. These include the standardization
f practices and methodologies, implementation of
central reporting system and provision of access
o specialized sensitivity testing and genotyping
ervices available at a few centers. The cycle of
ctive ongoing transmission should be stopped via
ctive case ﬁnding and screening most vulnerable
roups with most reliable tools. Diagnostic labora-
ory standards must be made uniform across the
ountry [7]. Furthermore, publication of accurate
nd up-to-date data will increase knowledge and
nderstanding of the current status. These require
he inclusion and commitment of all those ded-
cated to the provision of healthcare services to
atients with tuberculosis and adequate resource
nvestment.
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